TALLC

TALLC Corp is a biotechnology company focused on developing innovative immunotherapies for the treatment of autoimmune and inflammatory diseases. The company was founded by Dr. Michael Rosenblum and Dr. Abbas Abul, leveraging research from the University of California, San Francisco (UCSF) regarding T-cell biology and immune tolerance. TALLC's primary technological focus is the modulation of the T-cell-antigen-presenting cell (APC) interface to restore immune balance. Its lead candidate is a selective CD28 antagonist designed to inhibit T-cell activation more precisely than existing therapies. In early 2024, the company was acquired by Eli Lilly and Company, which integrated TALLC's assets into its immunology research and development pipeline. The acquisition highlights the potential of T-cell modulation to provide next-generation solutions for chronic inflammatory conditions.